(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number
WO 01/40207 A1

(51) International Patent Classification[7]: C07D 277/56, 263/34, 401/04, A61K 31/426, 31/421, A61P 3/06, 9/10

(21) International Application Number: PCT/EP00/11995

(22) International Filing Date:
30 November 2000 (30.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

9928561.1	2 December 1999 (02.12.1999)	GB
0003500.6	15 February 2000 (15.02.2000)	GB

(71) Applicant *(for all designated States except US)*: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: SIERRA, Michael, Lawrence [US/FR]; Laboratoire Glaxo Wellcome, Centre de Recherches, Z A de Courtaboeuf, 25 avenue de Quebec, F- 91940 Les Ulis (FR).

(74) Agent: LEAROYD, Stephanie, A.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*
— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/40207 A1

(54) Title: SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS HPPAR ALPHA ACTIVATORS



(I)

(57) Abstract: A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof wherein; X^1 represents O or S; R^1 and R^2 independently represent H, halogen, $-CH_3$ and $-OCH_3$; n represents 1 or 2; X_2 represents NH, NCH_3 or O; One of Y and Z is N, and the other is O or S; R^3 represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one or more halogen, NO_2, NH_2, CF_3, OCF_3, OC_{1-6} straight or branched alkyl, C_{1-6} straight or branched alkyl, alkenyl or alkynyl with the provision that when R^3 is pyridyl, the N is unsubstituted; R^4 represents CF_3 or CH_3.